To complement the first clinical analysis of SEMA3F, NRP1 and NRP2, which are poor prognostic markers for BC and DCIS, we further explored the clinical relevance of these proteins in DCIS and invasive BC tumors. Here, SEMA3F is linked to ductal breast carcinoma in situ.